Trials / Completed
CompletedNCT06897150
Carotegrast Methyl in Ulcerative Colitis
Efficacy and Safety of Carotegrast Methyl in Active Ulcerative Colitis: A Real-World Prospective Cohort Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Takayuki Yamamoto · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Carotegrast methyl, an oral α4-integrin inhibitor, was recently approved in Japan for the treatment of active ulcerative colitis (UC). However, real-world data regarding its efficacy and safety remain scarce. This study aimed to assess the clinical effectiveness and safety profile of carotegrast methyl in patients with active UC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Carotegrast methyl | a dosage of 960 mg three times daily |
Timeline
- Start date
- 2022-06-01
- Primary completion
- 2025-03-15
- Completion
- 2025-03-15
- First posted
- 2025-03-26
- Last updated
- 2025-04-02
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT06897150. Inclusion in this directory is not an endorsement.